Venus Remedies Receives Market Authorisations for two cancer drugs

Venus Remedies Ltd, a leading pharmaceutical company, announced that it has obtained approvals to market two important oncology medications (carboplatin and bortezomib) in Morocco and the Philippines.

"These approvals are pivotal in our strategy to expand our oncology range and meet the increasing global demand for cancer treatments. We are advancing toward becoming the leading oncology supplier in Southeast Asia," Saransh Chaudhary, president of Global Critical Care at Venus Remedies, said in a statement.

The Philippine market, ranked as the second largest in the ASEAN region, is projected to increase from USD 400 million in 2022 to USD 790 million by 2030. The statement declared that the approval of bortezomib will improve the company's capacity to provide advanced cancer treatments in Southeast Asia.

In Morocco, the approval of carboplatin is expected to boost Venus Remedies' position in the African oncology market, which is forecasted to reach USD 150.8 million by 2029.

Aditi K Chaudhary, president of the company's international business, said, "These authorisations reflect our commitment to providing innovative and accessible healthcare solutions worldwide."

Venus Remedies, located in Panchkula, currently has 15 approvals in Morocco and 69 in the Philippines. Venus is an Indian pharmaceutical company focused on research and developing creative solutions to enhance patient results. By prioritizing innovative research and development, the company has built a strong reputation for excellence within the pharmaceutical sector.